all quiet..., page-5

Thats a great post Colcom, thanks.

The main issue is still Lajolla's selling pressure and they now hold more shares than ever which they will want to offload then recharge from the convertible note. I don't think they will sell for less then 1.2c, but if the price reaches 1.3 and they convert another portion of their loan, their new holding will be at 1.04c and they will be happy to sell above this. Nasty downward spiral hey?

The only way out is a capital raising but this will result in large dilution at current levels. Looks like management are doing all they can to add value to the price with the recent announcements, however the last patent announcemnet had little effect. Other alternative is a partnering/funding agreement. Bone still only have a relatively small number of shares on issue compared to other biotechs.